Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results | Zendy

G Raguin | Zendy; Gwendoline Poizat | Zendy; Laurence MorandJoubert | Zendy; AnneMarie Taburet | Zendy; Clotilde Le Tiec | Zendy; François Clavel | Zendy; Geneviève Chêne | Zendy; PierreMarie Girard | Zendy

Open Access

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results

Author(s) -

G Raguin,

Gwendoline Poizat,

Laurence MorandJoubert,

AnneMarie Taburet,

Clotilde Le Tiec,

François Clavel,

Geneviève Chêne,

PierreMarie Girard

Publication year - 2006

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e3280118d6a

Subject(s) - amprenavir , lopinavir , ritonavir , lopinavir/ritonavir , virology , medicine , salvage therapy , reverse transcriptase inhibitor , viral load , sida , viral disease , human immunodeficiency virus (hiv) , biology , chemotherapy , antiretroviral therapy , enzyme , protease , biochemistry , hiv 1 protease

We report the results of the extended follow-up at one year of a randomized trial evaluating the virological efficacy of a salvage therapy combining lopinavir and amprenavir with either 200 or 400 mg/day ritonavir, along with optimized nucleoside reverse transcriptase inhibitors, in patients carrying multidrug-resistant isolates. The combination of amprenavir, lopinavir and ritonavir (400 mg/day) is durably potent, yielding a sustained virological response (HIV RNA < 50 copies) in 39% of cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research